Leukemia specialists: How advances in measurable residual disease (MRD) are improving cancer care
Measurable residual disease (MRD) is a monitoring tool that physicians use to assess the remission status of patients with leukemias, lymphomas, myelomas and other blood disorders.
Formerly known as “minimal residual disease,” this term describes a situation in which cancer cells are still present in the body after treatment, yet undetectable using current testing methods.
Diagnosis & Treatment
Stage IV breast cancer survivor: Why I celebrated my 100th round of chemotherapy
Find stories by topic
Find out everything you need to know to navigate a cancer diagnosis and treatment from MD Anderson’s experts.
